ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
June 1, 2026- Telix’s first-in-class lutetium radio antibody-drug conjugate (rADC) candidate, TLX591-Tx, demonstrates acceptable tolerability across all standard-of-care (SoC) combination cohorts, with no new safety signals.
- Findings support feasibility of TLX591-Tx in combination with contemporary SoC in post-ARPI metastatic castration-resistant prostate cancer (mCRPC).
Original URL: Click here to visit original article